CLS in study collaboration regarding treatment of advanced pancreatic cancer with the University Hospital in Verona, Italy
Clinical Laserthermia Systems (CLS) (publ), which develops and markets Interstitial Laser Thermo Therapy (imILTCLS), a polyclinical, heat-induced cancer immunotherapy for gentle and effective treatment of most types of solid cancer tumors, has accepted a proposal from the University Hospital in Verona, Italy, regarding a study focused on imILT treatment advanced pancreatic cancer.
CLS has been in contact with the hospital in Verona for some time and has recently been informed that the hospital has received approval by the ethics committee for the study, which will include 10 patients and is planned to start in late 2015 and estimated to be complete in December 2017.
"We are delighted that the University Hospital in Verona, one of the most well-regarded hospitals in Europe in the area of research and treatment of pancreatic cancer, has invited us to participate in a study. Pancreatic cancer is a prioritized indication for CLS and we are therefore very enthusiastic about the partnership," says CEO Lars-Erik Eriksson, CLS.
More information about Instituto del Pancreas at the University Hospital in Verona: www.chirurgiapancreasverona.it
Lars-Erik Eriksson, CEO, Clinical Laserthermia Systems AB (publ)
Tel: +46 – (0)702 – 90 33 00 E-mail: firstname.lastname@example.org
Clinical Laserthermia Systems AB (publ) develops and markets a safe, gentle, effective, and clinically documented therapy for treatment of solid cancer tumors. The product is based on immunostimulating interstitial laser thermotherapy (imILT). CLS is listed on Aktietorget under the stock symbol CLS B. More information is available on the Company's website www.clinicallaser.se